ISBT 2018

The 35th International congress of the ISBT (International Society of Blood Transfusion) will be held in Toronto, Canada from June 2 – 6, 2018.

We invite you to join us at ISBT at the following:

Cerus Symposium

The Cerus symposium will be held on Tuesday June 5 “Pathogen Inactivation Around the World: Setting the Standard for Blood Safety”.  This lunch symposium will provide a global perspective on the use and evolution of pathogen inactivation. Key opinion leaders from Europe, Latin America and the North America will discuss the need for pathogen inactivation, experiences in implementation, and clinical impact, all of which may have unique aspects specific to given regions.

Tuesday June 5, 2018 from 12:00 – 13:30 in room 718A at the Toronto Convention Center.


Laurence Corash, MD (Chair), Chief Scientific Officer, Cerus Corporation, California
United States

Europe: Nation-Wide Implementation and Over Seven Years of Experience with INTERCEPT Platelets in Switzerland

Behrouz Mansouri Taleghani PD Dr. med., MSc Head Physician, Divisional Director of Transfusion Medicine and Therapeutic Hemapheresis, Chairman Transfusion Committee Insel Group

INSELSPITAL, Universitätsspital Bern
Bern, Switzerland

Latin America: Ensuring Blood Availability and Protecting Patients from Arboviruses in Brazil

Silvano Wendel  MD, PhD Medical Director- Blood Bank, Hospital Sírio-Libanês, Centro de Imunologia e Imunogenética
São Paulo, Brazil

North America: A US Hospitals’ Perspective on the Routine Use of and Clinical Impact with Pathogen Inactivation

Mary Berg, MD Medical Director, Transfusion Services, Associate Professor of Pathology

University of Colorado Anschutz Medical Campus, Department of Pathology
Colorado, United States


Pathogen Inactivation Oral Presentations and Posters:

Oral # 3D-S14-04

  • Monday - June 4th, 2018: 17:00 - 17:15 | Location: Room 701 | Session: Pathogen Inactivation

Three Years Routine Experience of Manual Production of Double-Dose Buffy Coat Platelets and Pathogen Inactivation System INTERCEPT: Impact On Economy, Blood Safety and Blood Component Quality
HS Ahlzén, L Larsson

Oral # 3D-S14-05

  • Monday - June 4th, 2018: 17:15 - 17:30 | Location: Room 701 | Session: Pathogen Inactivation

No INTERCEPT (S-303/Glutathione)-Specific Antibodies Detected in a Phase III, Randomized, Controlled Study to Evaluate Pathogen-Inactivated Red Blood Cells in Thalassemia Major Patients (SPARC)
C Geisen, Y Aydinok, R Origa et al

Oral # 4C-S23-03

  • Tuesday – June 5th, 2018: 14:45 - 15:00 | Location : Room 718A | Session: Frozen Platelets

Release of Biologic Response Modifiers Following Cryopreservation of Pathogen Reduces and Non-Pathogen Reduced Platelet Concentrates

N Tynngård, P Sandgren

Poster Presentations:
The INTERCEPT Blood System will be featured in 16 posters at the congress.  The poster session is scheduled for Tuesday - June 5th from 17:45 – 18:45 at the Metro Toronto Convention Centre (MTCC) - South Building Poster Hall - located adjacent to the Exhibition Area.


  • P-240 – How to Standardise a Manual Platelet Production Process and the Impact of Optimisation on Platelet Volume and Quality
    L Larsson, HS Ahlzén
  • P-291 – Effect of a 24h and 40h CAD Time in Quality of Platelet Concentrate Treated by Amotosalen and Ultraviolet Light A
    H Isola, A Dupuis, A Eckly et al
  • P-299- In Vitro Characterization of Amotosalen-UVA Platelet Components Stored for 7 Days
    S Yegneswaran, JM Payrat, D Hanson et al
  • P-305- Amotosalen/UVA Treatment Can Inactivate Klebsiella Pneumoniae in WB-

Derived PC to Effective Sterility, After 7 Days of Storage
N Patel, K Tucker, S McNally et al

  • P-309 – Pathogen Inactivated Double Dose Buffy -Coat Platelet Concentrates Obtained with New Processing Sets Show Improved In Vitro Quality Over 7-Day Storage
    L Larsson, S Ohlsson, B Diedrich et al
  • P-311 – Production of Pathogen Inactivated Platelet Concentrates from Pools of 8 Buffy-Coats and Double Dose Apheresis
    C Naegelen, H Isola, N Marpaux et al
  • P-312 – In-Vitro Storage Quality of Platelet Concentrates Pathogen Inactivated Using Triple Storage Processing Sets Made of Alternate Plastics
    L Infanti, N Tschopp-Weber, A Plattner et al
  • P-316 – Evaluation of the Amotosalen/UVA Pathogen Inactivation Method for Platelets for Routine Use
    Tareq Mustafa
  • P-422 – Amotosalen-UVA Inactivates High Levels of Treponema Pallidum In Platelet Concentrates Suspended In 100% Plasma
    A Laughhunn, S Lukehart, B Molini et al
  • P-735- Clinical Efficacy of Single and Simultaneous Double Transfusions of Amotosalen/UVA Light Pathogen-Reduced Platelet Units
    R Ayupova, U Sultanbaev, S Madzaev et al


  • P-308 - Evaluation of Whole Blood Derived Plasma Prepared with the Amotosalen-

UVA Pathogen Inactivation with Reduced DEHP Plastics Processing Sets
F Varfaj, K Waldhaus, H Evans et al

  • P-320 - Retention of Thrombin Generation Activity in Pooled Whole Blood-Derived Plasma After Amotosalen-UVA Pathogen Inactivation and Storage is Independent of ABO Blood Groups
    C Ravanat, A Dupuis, N Marpaux et al


  • P-313 - Evaluation of Amotosalen/UVA Pathogen Inactivation for Plasma and Platelets
    M AlJohani, P Govindan, M Abdulmajeed et al


  • P-306 – Characterization of S-303/GSH Pathogen Inactivated Red Blood Cells and Conventional Red Blood Cells in a Chronic Transfusion Clinical Trial of Thalassemia Major Patients
    A Erickson, Y Aydinok, C Sonar et al
  • P-310 - Robustness of the Amustline/GSH Pathogen Inactivation System for Red Blood Cells Combined with Irradiation
    M Schott, B Warbington, G Villegas et al


P-436 - Nucleic Acid Targeted Technologies Inactivate High Levels of Plasmodium Falciparum in All Blood Components
A Laughhunn, C Sow, P Grellier et al


Cerus Booth:

Cerus will be exhibiting at booth # 111 in the main exhibition hall. Please visit us to learn more about Pathogen Inactivation.